JP2022510041A5 - - Google Patents

Info

Publication number
JP2022510041A5
JP2022510041A5 JP2021553755A JP2021553755A JP2022510041A5 JP 2022510041 A5 JP2022510041 A5 JP 2022510041A5 JP 2021553755 A JP2021553755 A JP 2021553755A JP 2021553755 A JP2021553755 A JP 2021553755A JP 2022510041 A5 JP2022510041 A5 JP 2022510041A5
Authority
JP
Japan
Prior art keywords
composition according
oligonucleotide
nucleic acid
sequence
spinocerebellar ataxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553755A
Other languages
English (en)
Japanese (ja)
Other versions
JP7714162B6 (ja
JP2022510041A (ja
JP7714162B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064054 external-priority patent/WO2020117702A1/en
Publication of JP2022510041A publication Critical patent/JP2022510041A/ja
Publication of JP2022510041A5 publication Critical patent/JP2022510041A5/ja
Application granted granted Critical
Publication of JP7714162B2 publication Critical patent/JP7714162B2/ja
Publication of JP7714162B6 publication Critical patent/JP7714162B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553755A 2018-12-03 2019-12-02 Msh3活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法 Active JP7714162B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862774791P 2018-12-03 2018-12-03
US62/774,791 2018-12-03
US201962877142P 2019-07-22 2019-07-22
US62/877,142 2019-07-22
PCT/US2019/064054 WO2020117702A1 (en) 2018-12-03 2019-12-02 Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity

Publications (4)

Publication Number Publication Date
JP2022510041A JP2022510041A (ja) 2022-01-25
JP2022510041A5 true JP2022510041A5 (cg-RX-API-DMAC10.html) 2022-12-09
JP7714162B2 JP7714162B2 (ja) 2025-07-29
JP7714162B6 JP7714162B6 (ja) 2025-09-08

Family

ID=70974779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553755A Active JP7714162B6 (ja) 2018-12-03 2019-12-02 Msh3活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法

Country Status (7)

Country Link
US (1) US20220072028A1 (cg-RX-API-DMAC10.html)
JP (1) JP7714162B6 (cg-RX-API-DMAC10.html)
KR (1) KR102970906B1 (cg-RX-API-DMAC10.html)
AU (1) AU2019394847A1 (cg-RX-API-DMAC10.html)
CA (1) CA3121779A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021006463A (cg-RX-API-DMAC10.html)
WO (2) WO2020117702A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216556A2 (en) * 2020-04-20 2021-10-28 University Of Massachusetts Oligonucleotides for msh3 modulation
EP4146807A4 (en) * 2020-05-08 2024-09-04 Takeda Pharmaceuticals U.S.A., Inc. METHODS OF TREATING NUCLEOTIDE AMPLIFICATION DISEASES ASSOCIATED WITH MSH3 ACTIVITY
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4247392A4 (en) * 2020-06-03 2025-10-08 Takeda Pharmaceuticals Usa Inc METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
EP4164656A4 (en) * 2020-06-11 2025-10-22 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
WO2022256631A2 (en) * 2021-06-04 2022-12-08 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
WO2023168304A2 (en) * 2022-03-02 2023-09-07 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
WO2024251211A1 (en) * 2023-06-06 2024-12-12 Revir Therapeutics, Inc. Compositions, methods, and systems for modulating splicing of msh3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010369A1 (en) * 1997-08-28 1999-03-04 Thomas Jefferson University Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US20140303235A1 (en) * 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
WO2015171918A2 (en) * 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3806850A2 (en) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
US11408000B2 (en) * 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
WO2022256631A2 (en) * 2021-06-04 2022-12-08 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

Similar Documents

Publication Publication Date Title
JP7155302B2 (ja) Atxn3を標的とするアンチセンスオリゴヌクレオチド
CA2071510C (en) 2' modified oligonucleotides
JP2005520489A5 (cg-RX-API-DMAC10.html)
JP2019141097A5 (cg-RX-API-DMAC10.html)
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
BRPI0811170B8 (pt) oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
JP2019534009A5 (cg-RX-API-DMAC10.html)
JPH07503856A (ja) プロテインキナーゼcのオリゴヌクレオチド調節
WO1994007367A9 (en) Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
TW201202418A (en) Treatment of Methionine Sulfoxide Reductase A (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
CA3241870A1 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
JP2006502243A5 (cg-RX-API-DMAC10.html)
JP2000514093A (ja) Cmv感染症の治療のための組成物および方法
JP2024522147A5 (cg-RX-API-DMAC10.html)
JP2021510512A5 (cg-RX-API-DMAC10.html)
JP2007530431A5 (cg-RX-API-DMAC10.html)
JP2004503232A5 (cg-RX-API-DMAC10.html)
JP2024536132A5 (cg-RX-API-DMAC10.html)
US20250376684A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
WO2022211129A1 (ja) Atn1のアンチセンスオリゴヌクレオチド誘導体
AU2018421460B2 (en) Therapeutic uses and methods
US20240336920A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
JP2022514648A (ja) Card9を標的とするアンチセンスオリゴヌクレオチド
CN114867856A (zh) Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP2007104971A (ja) ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド